{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:23:46Z","timestamp":1781519026555,"version":"3.54.1"},"reference-count":25,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:p>OBJECTIVE\u2014In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH).<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg\/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic\/diastolic blood pressure &amp;lt;130\/80 mmHg. ECG readings were centralized and blinded to treatment.<\/jats:p>\n               <jats:p>RESULTS\u2014Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24\u201348) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18\u20130.65], P = 0.0012 unadjusted, and 0.35 [0.18\u20130.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure\u2013lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population.<\/jats:p>","DOI":"10.2337\/dc08-0371","type":"journal-article","created":{"date-parts":[[2008,6,7]],"date-time":"2008-06-07T00:49:14Z","timestamp":1212799754000},"page":"1629-1634","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":36,"title":["Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"31","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"},{"name":"Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilian","family":"Iliev","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Maria","family":"Costa","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"},{"name":"Unit of Cardiovascular Diseases, Policlinico Sant'Orsola-Malpighi, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneliya","family":"Parvanova","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Antonio","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Motterlini","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ene-Iordache","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Rare Diseases \u201cAldo & Cele Dacco\u0300,\u201d Mario Negri Institute for Pharmacological Research, Bergamo, Italy"},{"name":"Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BENEDICT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031219055534400_R1","doi-asserted-by":"crossref","unstructured":"Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med\u2008114: 345\u2013352, 1991","DOI":"10.7326\/0003-4819-114-5-345"},{"key":"2022031219055534400_R2","doi-asserted-by":"crossref","unstructured":"Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med\u2008117:831\u2013836, 1992","DOI":"10.7326\/0003-4819-117-10-831"},{"key":"2022031219055534400_R3","doi-asserted-by":"crossref","unstructured":"Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med\u2008322:1561\u20131566, 1990","DOI":"10.1056\/NEJM199005313222203"},{"key":"2022031219055534400_R4","doi-asserted-by":"crossref","unstructured":"Kannel WB: Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med\u200875:4\u201311, 1983","DOI":"10.1016\/0002-9343(83)90111-0"},{"key":"2022031219055534400_R5","doi-asserted-by":"crossref","unstructured":"Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension\u20087:105\u2013112, 1985","DOI":"10.1161\/01.HYP.7.1.105"},{"key":"2022031219055534400_R6","doi-asserted-by":"crossref","unstructured":"Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation\u2008104:1615\u20131621, 2001","DOI":"10.1161\/hc3901.096700"},{"key":"2022031219055534400_R7","doi-asserted-by":"crossref","unstructured":"Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation\u2008108:684\u2013690, 2003","DOI":"10.1161\/01.CIR.0000083724.28630.C3"},{"key":"2022031219055534400_R8","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G: Preventing microalbuminuria in type 2 diabetes. N Engl J Med\u2008351:1941\u20131951, 2004","DOI":"10.1056\/NEJMoa042167"},{"key":"2022031219055534400_R9","doi-asserted-by":"crossref","unstructured":"Bella JN, Devereux RB, Roman MJ, Palmieri V, Liu JE, Paranicas M, Welty TK, Lee ET, Fabsitz RR, Howard BV: Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol\u200887:1260\u20131265, 2001","DOI":"10.1016\/S0002-9149(01)01516-8"},{"key":"2022031219055534400_R10","doi-asserted-by":"crossref","unstructured":"Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med\u2008157:1413\u20131418, 1997","DOI":"10.1001\/archinte.157.13.1413"},{"key":"2022031219055534400_R11","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G: Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT Trial. J Am Soc Nephrol\u200817:3472\u20133481, 2006","DOI":"10.1681\/ASN.2006060560"},{"key":"2022031219055534400_R12","doi-asserted-by":"crossref","unstructured":"Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads: 1949. Ann Noninvasive Electrocardiol\u20086:343\u2013368, 2001","DOI":"10.1111\/j.1542-474X.2001.tb00129.x"},{"key":"2022031219055534400_R13","doi-asserted-by":"crossref","unstructured":"Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation\u2008104:2039\u20132044, 2001","DOI":"10.1161\/hc4201.097944"},{"key":"2022031219055534400_R14","doi-asserted-by":"crossref","unstructured":"Linz W, Schaper J, Wiemer G, Albus U, Scholkens BA: Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol\u2008107:970\u2013975, 1992","DOI":"10.1111\/j.1476-5381.1992.tb13393.x"},{"key":"2022031219055534400_R15","doi-asserted-by":"crossref","unstructured":"Mitchell GF, Pfeffer MA, Finn PV, Pfeffer JM: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation\u200894:2923\u20132929, 1996","DOI":"10.1161\/01.CIR.94.11.2923"},{"key":"2022031219055534400_R16","doi-asserted-by":"crossref","unstructured":"Topouchian J, Asmar R, Sayegh F, Rudnicki A, Benetos A, Bacri AM, Safar ME: Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke\u200830:1056\u20131064, 1999","DOI":"10.1161\/01.STR.30.5.1056"},{"key":"2022031219055534400_R17","doi-asserted-by":"crossref","unstructured":"Aceto JF, Baker KM: [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol\u2008258:H806\u2013813, 1990","DOI":"10.1152\/ajpheart.1990.258.3.H806"},{"key":"2022031219055534400_R18","doi-asserted-by":"crossref","unstructured":"Passier RC, Smits JF, Verluyten MJ, Daemen MJ: Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol\u2008271:H1040\u20131048, 1996","DOI":"10.1152\/ajpheart.1996.271.3.H1040"},{"key":"2022031219055534400_R19","doi-asserted-by":"crossref","unstructured":"Fernandez-Alfonso MS, Kreutz R, Zeh K, Liu Y, Ganten D, Paul M: Differential regulation of vascular angiotensin I-converting enzyme in hypertension. Hypertension\u200824:280\u2013286, 1994","DOI":"10.1161\/01.HYP.24.3.280"},{"key":"2022031219055534400_R20","doi-asserted-by":"crossref","unstructured":"Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M: Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA\u200897:931\u2013936, 2000","DOI":"10.1073\/pnas.97.2.931"},{"key":"2022031219055534400_R21","doi-asserted-by":"crossref","unstructured":"Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ: Blood pressure-independent attenuation of cardiac hypertrophy by AT1R-AS gene therapy. Hypertension\u200839:969\u2013975, 2002","DOI":"10.1161\/01.HYP.0000017827.63253.16"},{"key":"2022031219055534400_R22","doi-asserted-by":"crossref","unstructured":"Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA\u2008103:17985\u201317990, 2006","DOI":"10.1073\/pnas.0605545103"},{"key":"2022031219055534400_R23","doi-asserted-by":"crossref","unstructured":"Linz W, Scholkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol\u2008105:771\u2013772, 1992","DOI":"10.1111\/j.1476-5381.1992.tb09054.x"},{"key":"2022031219055534400_R24","doi-asserted-by":"crossref","unstructured":"Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab\u200816:120\u2013126, 2005","DOI":"10.1016\/j.tem.2005.02.003"},{"key":"2022031219055534400_R25","unstructured":"Safar ME, Laurent SL, Bouthier JD, London GM, Mimran AR: Effect of converting enzyme inhibitors on hypertensive large arteries in humans. J Hypertens Suppl\u20084:S285\u2013S289, 1986"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/8\/1629\/599528\/zdc00808001629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/8\/1629\/599528\/zdc00808001629.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T20:24:24Z","timestamp":1647116664000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/31\/8\/1629\/28441\/Preventing-Left-Ventricular-Hypertrophy-by-ACE"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc08-0371","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}